7505-93-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Production:
2-Cyano-2-MethylpropanaMide is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Organic Synthesis:
As a chemical reagent, 2-Cyano-2-MethylpropanaMide is used to introduce the cyano group into organic molecules, facilitating the synthesis of a wide range of organic compounds.
Used in Diabetes and Metabolic Disorder Treatment Research:
2-Cyano-2-MethylpropanaMide is being investigated for its potential use in the treatment of type 2 diabetes and other metabolic disorders due to its ability to activate peroxisome proliferator-activated receptor gamma (PPARγ), a target for antidiabetic drugs.
It is crucial to handle 2-Cyano-2-MethylpropanaMide with care, as it is classified as a hazardous substance that can cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C5H8N2O/c1-5(2,3-6)4(7)8/h1-2H3,(H2,7,8)

Upstream product

• 107-91-5 cyanoacetic acid amide 
• 74-88-4 methyl iodide 
• 86439-20-5 2,2-dimethyl-3-oximinoadipamide 
• 72291-30-6 methyl 2,2-dimethyl-cyanoacetate 
• 1572-98-1 2-cyano-2-methyl-propionic acid ethyl ester 
• 22426-30-8 2-cyano-2-methylpropanoic acid 

Downstream Products

• 666844-61-7 (2-carbamoyl-2-methylpropyl)carbamic acid benzyl ester 
• 173338-07-3 tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate 
• 324763-51-1 aminopivalinamide 
• 173334-57-1 (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide 
• 173334-58-2 (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxypropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-(2-propan-2-yl)nonanamide hemifumarate 
• 324763-47-5 (2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide 
• 20762-07-6 2-Cyan-2-methyl-propionsaeure-dianilinophosphorylamid 
• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 7321-55-3 2,2-dimethylmalononitrile 

Relevant academic research and scientific papers

FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis

A previous publication from this lab (Patrick, et al. Bioorg. Med. Chem. 2016, 24, 2451-2465) explored the antitrypanosomal activities of novel derivatives of 2-(2-benzamido)ethyl-4-phenylthiazole (1), which had been identified as a hit against Trypanosoma brucei, the causative agent of human African trypanosomiasis. While a number of these compounds, particularly the urea analogues, were quite potent, these molecules as a whole exhibited poor metabolic stability. The present work describes the synthesis of 65 new analogues arising from medicinal chemistry optimization at different sites on the molecule. The most promising compounds were the urea derivatives of 2-aryl-benzothiazol-5-amines. One such analogue, (S)-2-(3,4-difluorophenyl)-5-(3-fluoro-N-pyrrolidylamido)benzothiazole (57) was chosen for in vivo efficacy studies based upon in vitro activity, metabolic stability, and brain penetration. This compound attained 5/5 cures in murine models of both early and late stage human African trypanosomiasis, representing a new lead for the development of drugs to combat this neglected disease.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES

The present application relates to a process for the preparation of aliskiren and its pharmaceutically acceptable salts. In particular, the present application relates to a process for the preparation of intermediates for aliskiren, and their conversion to aliskiren or its salts.

PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF

The present invention relates to a process for the preparation of (2S,4S,5S,7S)-N-(2- Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxy propoxy )phenyl]-octanamide compound of formula- 1 and its pharmaceutically acceptable salts thereof. Further, relates to the processes for the preparation of (R)-4-(2-(halomethyl)-3- methylbutyl)-l-methoxy-2-(3-methoxypropoxy) benzene and (R)-2-(4-methoxy-3-(3-methoxy propoxy) benzyl)-3-methyIbutan-l-ol useful intermediates in the synthesis of compound of formula- 1.

A PROCESS FOR DIMETHYLATION OF ACTIVE METHYLENE GROUPS

The present invention discloses a process for dimethylation of active methylene groups. Specifically, the invention discloses aprocess for preparing3-amino-2,2- dimethylpropanamide. Compounds produced by the present dimethylation process such as 3-amino-2,2-dimethylpropanamide can be used as intermediates in the route of synthesis of therapeutic, prophylactic or diagnostic agent, for example aliskiren or cryptophycin. Particularly, the invention relates to embodiments further extending to processesfor preparing pharmaceutical dosage form comprising said therapeutic, prophylactic or diagnostic agents. More specifically, the invention relates to the use of compounds produced by the present dimethylation process for the manufacture of therapeutic, prophylactic or diagnostic agents or for the manufacture of pharmaceutical dosage forms comprising said therapeutic, prophylactic or diagnostic agents. The processes according to the present invention can be beneficially applied for the synthesis of various active pharmaceutical ingredients, such as aliskiren or crypthophycin.

Practical synthesis of an orally active renin inhibitor aliskiren

A convergent synthesis of aliskiren was accomplished via the use of Segment AB as the key intermediate, which was prepared via the coupling of the Grignard reagent derived from Segment B with Segment A, followed by subsequent oxidative lactonization.

A NOVEL REACTION OF α,γ-DINITRO COMPOUNDS. TRANSFORMATION OF METHYL 4,6-DINITRO-5,5-DIMETHYLHEXANOATE TO 2,2-DIMETHYL-3-OXIMINOADIPATE AND SUBSEQUENT CYCLIZATION TO 3-(4,4-DIMETHYL-5-KETO-3-ISOXAZOLE)PROPIONIC ACID

Methyl 4,6-dinitro-5,5-dimethylhexanoate (2) is converted by catalytic quantities of sodium methoxide and ammonia to dimethyl 2,2-dimethyl-3-oximinoadipate (10) and 2,2-dimethyl-3-oximinoadipamide (11), respectively.On treatment with dilute acid, compounds 10 and 11 are readily cyclized to 3-(4,4-dimethyl-5-keto-3-isoxazole)propionic acid (3).Compound 3 is also obtained directly from compound 2 on treatment with base and subsequent acidification.